Carroll Financial Associates’s DexCom DXCM Stock Holding History

Carroll Financial Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$67K	Sell	472 -1,376	-74%	-$198K	﹤0.01%	638
2021 Q3	$252K	Sell	1,848 -420	-19%	-$53K	0.01%	353
2021 Q2	$242K	Buy	2,268 +1,856	+450%	+$178K	0.01%	372
2021 Q1	$37K	Buy	412 +100	+32%	+$9.39K	﹤0.01%	833
2020 Q4	$28K	Hold	312	–	–	﹤0.01%	837
2020 Q3	$32K	Sell	312 -320	-51%	-$33.4K	﹤0.01%	753
2020 Q2	$64K	Buy	632 +320	+103%	+$28.6K	0.01%	591
2020 Q1	$21K	Hold	312	–	–	﹤0.01%	767
2019 Q4	$17K	Hold	312	–	–	﹤0.01%	909
2019 Q3	$11K	Hold	312	–	–	﹤0.01%	962
2019 Q2	$11K	Sell	312 -412	-57%	-$13K	﹤0.01%	975
2019 Q1	$21K	Buy	724 +412	+132%	+$14.5K	﹤0.01%	735
2018 Q4	$10K	Hold	312	–	–	﹤0.01%	845
2018 Q3	$11K	Sell	312 -312	-50%	-$9.67K	﹤0.01%	863
2018 Q2	$14K	Hold	624	–	–	﹤0.01%	781
2018 Q1	$11K	Hold	624	–	–	﹤0.01%	806
2017 Q4	$8K	Hold	624	–	–	﹤0.01%	880
2017 Q3	$7K	Hold	624	–	–	﹤0.01%	888
2017 Q2	$11K	Hold	624	–	–	﹤0.01%	813
2017 Q1	$13K	Buy	+624	New	+$12.2K	﹤0.01%	761

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carroll Financial Associates's DXCM Position: Q4 2021 in Review

Carroll Financial Associates reduced its DexCom (DXCM) stake by 74% in Q4 2021, selling an estimated $198K and leaving 472 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #638.

Carroll Financial Associates first reported a position in DXCM in Q1 2017 and has held it in 20 quarters since. The position peaked at $252K in Q3 2021. 931 funds tracked by Wall St. Rank hold DXCM as of Q4 2021.

Carroll Financial Associates held 472 shares of DexCom worth $67K as of Q4 2021.
Carroll Financial Associates sold 1,376 DexCom shares in Q4 2021, an estimated $198K.
DexCom made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #638 holding.
Carroll Financial Associates first reported a position in DexCom in Q1 2017 and has held it in 20 quarters since.
Carroll Financial Associates's DexCom position peaked at $252K in Q3 2021.
931 funds tracked by Wall St. Rank held DexCom as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.